214 related articles for article (PubMed ID: 19540337)
21. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
22. Extrinsic signals determine myeloid-erythroid lineage switch in MN1 leukemia.
Heuser M; Park G; Moon Y; Berg T; Xiang P; Kuchenbauer F; Vollett S; Lai C; Humphries RK
Exp Hematol; 2010 Mar; 38(3):174-9. PubMed ID: 20096329
[TBL] [Abstract][Full Text] [Related]
23. Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling.
Yamamoto Y; Tsuzuki S; Akahori Y; Ukai Y; Sumitomo M; Murayama Y; Yamamoto K; Inaguma Y; Tokuda M; Abe A; Akatsuka Y; Emi N; Kurosawa Y
Cancer Sci; 2012 Feb; 103(2):350-9. PubMed ID: 22049994
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816.
Kim SY; Kang JJ; Lee HH; Kang JJ; Kim B; Kim CG; Park TK; Kang H
Biochem Biophys Res Commun; 2011 Jul; 410(2):224-8. PubMed ID: 21640708
[TBL] [Abstract][Full Text] [Related]
25. FLT3 inhibitors in acute myeloid leukemia.
el-Shami K; Stone RM; Smith BD
Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
[TBL] [Abstract][Full Text] [Related]
26. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.
Heidary DK; Huang G; Boucher D; Ma J; Forster C; Grey R; Xu J; Arnost M; Choquette D; Chen G; Zhou JH; Yao YM; Ball ED; Namchuk M; Davies RJ; Henkel G
J Med Chem; 2012 Jan; 55(2):725-34. PubMed ID: 22221201
[TBL] [Abstract][Full Text] [Related]
27. Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner.
Mitina O; Warmuth M; Krause G; Hallek M; Obermeier A
Ann Hematol; 2007 Nov; 86(11):777-85. PubMed ID: 17668209
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in AML in relation to (ab)normal karyotype.
Stone RM
Best Pract Res Clin Haematol; 2009 Dec; 22(4):523-8. PubMed ID: 19959103
[TBL] [Abstract][Full Text] [Related]
29. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML.
Zheng R; Klang K; Gorin NC; Small D
Leuk Res; 2004 Feb; 28(2):121-6. PubMed ID: 14654075
[TBL] [Abstract][Full Text] [Related]
30. A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.
Cai B; Liu Y; Chong Y; Mori SF; Matsunaga A; Zhang H; Fang X; Chang CS; Cowell JK; Hu T
Mol Cancer; 2022 Jul; 21(1):156. PubMed ID: 35906694
[TBL] [Abstract][Full Text] [Related]
31. Signal transduction of oncogenic Flt3.
Choudhary C; Müller-Tidow C; Berdel WE; Serve H
Int J Hematol; 2005 Aug; 82(2):93-9. PubMed ID: 16146838
[TBL] [Abstract][Full Text] [Related]
32. [FLT3 inhibitors for acute myeloid leukemia].
Kiyoi H
Nihon Rinsho; 2014 Jun; 72(6):1035-41. PubMed ID: 25016800
[TBL] [Abstract][Full Text] [Related]
33. Lestaurtinib: a multi-targeted FLT3 inhibitor.
Fathi AT; Levis M
Expert Rev Hematol; 2009 Feb; 2(1):17-26. PubMed ID: 21082990
[TBL] [Abstract][Full Text] [Related]
34. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.
Takahashi S
J Hematol Oncol; 2011 Apr; 4():13. PubMed ID: 21453545
[TBL] [Abstract][Full Text] [Related]
35. Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
Herrmann MD; Lennerz JK; Bullinger L; Bartholomae S; Holzmann K; Westhoff MA; Corbacioglu S; Debatin KM
Exp Hematol; 2014 Feb; 42(2):90-100. PubMed ID: 24211243
[TBL] [Abstract][Full Text] [Related]
36. Implications of FLT3 mutations in the therapy of acute myeloid leukemia.
Mattison RJ; Ostler KR; Locke FL; Godley LA
Rev Recent Clin Trials; 2007 May; 2(2):135-41. PubMed ID: 18473998
[TBL] [Abstract][Full Text] [Related]
37. FLT3 and acute myelogenous leukemia: biology, clinical significance and therapeutic applications.
Advani AS
Curr Pharm Des; 2005; 11(26):3449-57. PubMed ID: 16250847
[TBL] [Abstract][Full Text] [Related]
38. Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia.
Tickenbrock L; Hehn S; Sargin B; Evers G; Ng PR; Choudhary C; Berdel WE; Müller-Tidow C; Serve H
Int J Hematol; 2008 Sep; 88(2):174-180. PubMed ID: 18668305
[TBL] [Abstract][Full Text] [Related]
39. Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia.
Murray HC; Miller K; Brzozowski JS; Kahl RGS; Smith ND; Humphrey SJ; Dun MD; Verrills NM
Mol Cell Proteomics; 2023 Mar; 22(3):100503. PubMed ID: 36682716
[TBL] [Abstract][Full Text] [Related]
40. The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment.
Bougherara H; Subra F; Crépin R; Tauc P; Auclair C; Poul MA
Mol Cancer Res; 2009 Sep; 7(9):1525-33. PubMed ID: 19737976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
